Kinase inhibitors and monoclonal antibodies in oncology: Clinical implications

Nature Reviews Clinical Oncology

Volumn 13, Issue 4, 2016, Pages 209-227

  Gharwan, Helen ^a   Groninger, Hunter ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; ALEMTUZUMAB; AXITINIB; B RAF KINASE; BCR ABL PROTEIN; BEVACIZUMAB; BLINATUMOMAB; BOSUTINIB; CABOZANTINIB; CD52 ANTIGEN; CERITINIB; CRIZOTINIB; CYTOTOXIC AGENT; DABRAFENIB; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ERLOTINIB; FLT3 LIGAND; GEFITINIB; INSULIN RECEPTOR; MONOCLONAL ANTIBODY; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN RET; SCATTER FACTOR RECEPTOR; STEM CELL FACTOR RECEPTOR; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ABDOMINAL PAIN; ACNE; ACUTE KIDNEY FAILURE; ACUTE LYMPHOBLASTIC LEUKEMIA; ALOPECIA; ANEMIA; ARTERY EMBOLISM; ARTERY THROMBOSIS; ARTHRALGIA; ASTHENIA; AUTOIMMUNE DISEASE; B CELL LEUKEMIA; B CELL LYMPHOMA; BLEEDING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRADYCARDIA; CANCER CELL; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CARCINOGENESIS; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; CONGESTIVE CARDIOMYOPATHY; CONSTIPATION; CORNEA ULCER; COUGHING; CYTOKINE RELEASE SYNDROME; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; DEPRESSION; DIARRHEA; DIGESTIVE SYSTEM FISTULA; DIGESTIVE SYSTEM PERFORATION; DYSPNEA; EDEMA; ELECTROLYTE DISTURBANCE; ENDOCRINE DISEASE; EPSTEIN BARR VIRUS INFECTION; EYE TOXICITY; FAINTNESS; FATIGUE; FEBRILE NEUTROPENIA; FEVER; FOLLICULITIS; GASTROINTESTINAL TOXICITY; GRAVES DISEASE; HAIR DISEASE; HAND FOOT SYNDROME; HEADACHE; HEALTH CARE COST; HEART ARRHYTHMIA; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEMORRHAGIC COLITIS; HUMAN; HYPERGLYCEMIA; HYPERKERATOSIS; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; INFLAMMATION; INTERSTITIAL LUNG DISEASE; INTERSTITIAL NEPHRITIS; INTESTINE OBSTRUCTION; INTESTINE PERFORATION; KIDNEY CARCINOMA; LIVER TOXICITY; LOSS OF APPETITE; LUNG DISEASE; LUNG EMBOLISM; LUNG TOXICITY; MALIGNANT NEOPLASTIC DISEASE; MEDICAL EXPERT; MELANOMA; METASTASIS; MOLECULARLY TARGETED THERAPY; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NON SMALL CELL LUNG CANCER; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PANCREATITIS; PARONYCHIA; PERICARDIAL EFFUSION; PERITONEUM CANCER; PHYSICIAN; PLEURA EFFUSION; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEINURIA; PUSTULE; QT PROLONGATION; QUALITY OF LIFE; RASH; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; REVIEW; SECOND CANCER; SEIZURE; SEPSIS; SIDE EFFECT; SKIN CANCER; SKIN CARCINOMA; SKIN TOXICITY; STEVENS JOHNSON SYNDROME; STOMATITIS; TERMINAL CARE; THROMBOCYTOPENIA; THROMBOEMBOLISM; THYROID CANCER; TOXIC EPIDERMAL NECROLYSIS; TOXIC HEPATITIS; TUMOR BLEEDING; UPPER RESPIRATORY TRACT INFECTION; UTERINE CERVIX CANCER; UTERINE TUBE TUMOR; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; VISUAL DISORDER; VOMITING; WOUND DEHISCENCE; ADVERSE EFFECTS; CLASSIFICATION; DISEASE MANAGEMENT; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; NEOPLASMS; PREMEDICATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DISEASE MANAGEMENT; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PREMEDICATION; PROTEIN KINASE INHIBITORS;

EID: 84952690771     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2015.213     Document Type: Review

References (248)

1. Krause, D. S., & Van Etten, R. A. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 353, 172-187 (2005
2. Amir, E., et al. Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs. J. Clin. Oncol. 29, 2543-2549 (2011
3. DiMasi, J. A., & Grabowski, H. G. Economics of new oncology drug development. J. Clin. Oncol. 25, 209-216 (2007
4. Piccart-Gebhart M. J., et al. Trastuzumab after adjuvant chemotherapy in HER2 positive breast cancer. N. Engl. J. Med. 353, 1659-1672 (2005
5. Slamon D. J., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001
6. Druker B. J., et al. Five-year follow up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408-2417 (2006
7. Baldo, B. A., & Pham, N. H. Adverse reactions to targeted and non-Targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch. Cancer Metastasis Rev. 32, 723-761 (2013
8. Niraula S., et al. The price we pay for progress: a meta-Analysis of harms of newly approved anticancer drugs. J. Clin. Oncol. 30, 3012-3019 (2012
9. Funakoshi, T., Latif, A., & Galsky, M. D. Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: a systematic review and meta-Analysis of randomized controlled trials. Cancer Treat. Rev. 40, 636-647 (2014
10. Yancik, R., Ganz, P. A., Varricchio, C. G., & Conley, B. Perspectives on comorbidity and cancer in older patients: approaches to expand the knowledge base. J. Clin. Oncol. 19, 1147-1151 (2001
11. Pajares B., et al. Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations. Clin. Transl. Oncol. 14, 94-101 (2012
12. Hartmann, J. T., Haap, M., Kopp, H. G., & Lipp, H. P. Tyrosine kinase inhibitors-A review on pharmacology, metabolism and SEs. Curr. Drug Metab. 10, 470-481 (2009
13. Imai, K., & Takaoka, A. Comparing antibody and small-molecule therapies for cancer. Nat. Rev. Cancer 6, 714-727 (2006
14. Dassonville, O., Bozec, A., Fischel, J. L., & Milano, G. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors: similarities and differences. Crit. Rev. Oncol. Hematol. 62, 53-61 (2007
15. Chari, R. V. J. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc. Chem. Res. 41, 98-107 (2008
16. Köhler, G., & Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495-497 (1975
17. Carter, P. Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer 1, 118-129 (2001
18. Beck, A., Wurch, T., & Corvaia, N. Therapeutic antibodies and derivatives: from the bench to the clinic. Curr. Pharm. Biotechnol. 9, 421-422 (2008
19. Nelson, A. L., Dhimolea, E., & Reichert, J. M. Development trends for human monoclonal antibody therapeutics. Nat. Rev. Drug Discov. 9, 767-774 (2010
20. Oldham, R. K., & Dillman, R. O. Monoclonal antibodies in cancer therapy: 25 years of progress. J. Clin. Oncol. 26, 1774-1777 (2008
21. Nissim, A., & Chernajovsky, Y. Historical development of monoclonal antibody therapeutics. Handb. Exp. Pharmacol. 181, 3-18 (2008
22. Yamada, T. Therapeutic monoclonal antibodies. Keio J. Med. 60, 37-46 (2011
23. Scott, A. M., Wolchok, J. D., & Old, L. J. Antibody therapy of cancer. Nat. Rev. Cancer 12, 278-287 (2012
24. Widmer N., et al. Review of therapeutic drug monitoring of anticancer drugs part two-Targeted therapies. Eur. J. Cancer 50, 2020-2036 (2014
25. Huang S., et al. Dual-Agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res. 64, 5355-5362 (2004
26. Lee, S. J., & Kavanaugh, A. Adverse reactions to biologic agents: focus on autoimmune disease therapies. J. Allergy Clin. Immunol. 116, 900-905 (2005
27. Pichler, W. J. Adverse SEs to biologic agent. Allergy 61, 912-920 (2006
28. Albini A., et al. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J. Natl Cancer Inst. 102, 14-25 (2010
29. O'Brien S. G., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348, 994-1004 (2003
30. Dy, G. K., & Adjei, A. A. Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J. Clin. 63, 249-279 (2013
31. Lambertini, M., Peccatori, F. A., & Azim, H. A. Jr. Targeted agents for cancer treatment during pregnancy. Cancer Treat. Rev. 41, 301-309 (2015
32. Riechelmann R. P., et al. Potential drug interactions and duplicate prescriptions among cancer patients. J. Natl Cancer Inst. 99, 592-600 (2007
33. Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature 414, 105-111 (2001
34. Dean, M., Fojo, T., & Bates, S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 5, 275-284 (2005
35. Reslan, L., Dalle, S., & Dumontet, C. Understanding and circumventing resistance to anticancer monoclonal antibodies. MAbs 1, 222-229 (2009
36. Perez-Soler, R. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. Clin. Lung Cancer 8, S7-S14 (2006
37. Chen, M. H. Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue. Curr. Cardiol. Rep. 11, 167-174 (2009
38. Ewer M. S., et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J. Clin. Oncol. 23, 7820-7826 (2005
39. Force, T., Krause, D. S., & Van Etten, R. A. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat. Rev. Cancer 7, 332-344 (2007
40. Chen, M. H., Kerkelä, R., & Force, T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation 118, 84-95 (2008
41. Shakir, D. K., & Rasul, K. I. Chemotherapy induced cardiomyopathy: pathogenesis, monitoring and management. J. Clin. Med. Res. 1, 8-12 (2009
42. Seidman A., et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J. Clin. Oncol. 20, 1215-1221 (2002
43. Bria E., et al. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-Analysis of the randomized trials. Breast Cancer Res. Treat. 109, 231-239 (2008
44. Perez E. A., et al. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin. Proc. 83, 679-686 (2008
45. Chen T., et al. Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-Analysis. Cancer Treat. Rev. 37, 312-320 (2011
46. Lenihan D., et al. Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. Ann. Oncol. 23, 791-800 (2012
47. Svoboda M., et al. Cardiac toxicity of targeted therapies used in the treatment for solid tumours: a review. Cardiovasc. Toxicol. 12, 191-207 (2012
48. Chu T. F., et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370, 2011-2019 (2007
49. Schmidinger M., et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 26, 5204-5212 (2008
50. Shah, R. R., Morganroth, J., & Shah, D. R. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). Drug Saf. 36, 295-316 (2013
51. Vaughn, C., Zhang, L., & Schiff, D. Reversible posterior leukoencephalopathy syndrome in cancer. Curr. Oncol. Rep. 10, 86-91 (2008
52. Lee, E. Q., Arrillaga-Romany, I. C., & Wen, P. Y. Neurologic complications of cancer drug therapies. Continuum (Minneap. Minn.) 18, 355-365 (2012
53. Quintás-Cardama A., et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J. Clin. Oncol. 25, 3908-3914 (2007
54. Montani D., et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 125, 2128-2137 (2012
55. Rothenstein, J. M., & Letarte, N. Managing treatment-related adverse events associated with Alk inhibitors. Curr. Oncol. 21, 19-26 (2014
56. Ou, S. H., Azada, M., Dy, J., & Stiber, J. A. Asymptomatic profound sinus bradycardia (heart rate =45) in non-small cell lung cancer patients treated with crizotinib. J. Thorac. Oncol. 6, 2135-2137 (2011
57. Ou S. H., et al. Heart rate decrease during crizotinib treatment and potential correlation to clinical response. Cancer 119, 1969-1975 (2013
58. Scappaticci, F. A., et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J. Natl Cancer Inst. 99, 1232-1239 (2007); erratums 100, 156 (2008), 100, 685 (2008
59. Grivas, A. A., Trafalis, D. T., & Athanassiou, A. E. Implication of bevacizumab in fatal arterial thromboembolic incidents. J. BUON 14, 115-117 (2009
60. Patel, J. N., et al. Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). Cancer 121, 1025-1031 (2015
61. Hurwitz H. I., et al. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J. Clin. Oncol. 29, 1757-1764 (2011
62. Nalluri S. R., et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-Analysis. JAMA 300, 2277-2285 (2008
63. Chu, D., & Wu, S. Risk of venous thromboembolism with bevacizumab in cancer patients-reply. JAMA 301, 1435-1436 (2009
64. Ferroni, P., Formica, V., Roselli, M., & Guadagni, F. Thromboembolic events in patients treated with anti-Angiogenic drugs. Curr. Vasc. Pharmacol. 8, 102-113 (2010
65. Schutz F. A., et al. Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Ann. Oncol. 22, 1404-1412 (2011
66. Choueiri T. K., et al. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-Analysis of clinical trials. J. Clin. Oncol. 28, 2280-2285 (2010
67. Sonpavde G., et al. Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-Analysis of randomized clinical trials. Crit. Rev. Oncol. Hematol. 87, 80-89 (2013
68. Kantarjian H., et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 362, 2260-2270 (2010
69. Clark O. A., et al. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-Analysis of randomized controlled trials. J. Clin. Oncol. 23, 4198-4214 (2005
70. Barber, N. A., Afzal, W., & Akhtari, M. Hematologic toxicities of small molecule tyrosine kinase inhibitors. Target Oncol. 6, 203-215 (2011
71. Gibson, R. J., & Stringer, A. M. Chemotherapy-induced diarrhoea. Curr. Opin. Support. Palliat. Care 3, 31-35 (2009
72. Stein, A., Voigt, W., & Jordan, K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther. Adv. Med. Oncol. 2, 51-63 (2010
73. Lu Y. Y., et al. Clinical observations on associations between the UGT1A1 genotype and severe toxicity of irinotecan. Asian Pac. J. Cancer Prev. 15, 3335-3341 (2014
74. Loriot Y., et al. Drug insight: gastrointestinal and hepatic adverse effects of molecular-Targeted agents in cancer therapy. Nat. Clin. Pract. Oncol. 5, 268-278 (2008
75. Thomas S. K., et al. Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. Clin. Lung Cancer 7, 326-331 (2006
76. Kanazawa S., et al. Aspirin reduces adverse effects of gefitinib. Anticancer Drugs 17, 423-427 (2006
77. Demetri G. D., et al. Efficacity and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347, 472-480 (2002
78. Van Glabbeke, M., et al. Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC ISG-AGITG). Eur. J. Cancer 42, 2277-2278 (2006
79. Uribe, J. M., Gelbmann, C. M., Traynor-Kaplan, A. E., & Barrett, K. E. Epidermal growth factor inhibits Ca2+-dependent Cl- transport in T84 human colonic epithelial cells. Am. J. Physiol. 271, C914-922 (1996
80. Melosky, B. Supportive care treatments for toxicities of anti-EGFR and other targeted agents. Curr. Oncol. 19, S59-S63 (2012
81. Hirsh V., et al. Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors. Curr. Oncol. 21, 329-336 (2014
82. Ohyashiki K., et al. Imatinib mesylate-induced hepato-Toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis. Leukemia 16, 2160-2161 (2002
83. James C., et al. Histological features of acute hepatitis after imatinib mesylate treatment. Leukemia 14, 978-979 (2003
84. Kikuchi S., et al. Severe hepatitis and complete molecular response caused by imatinib mesylate: possible association of its serum concentration with clinical outcomes. Leuk. Lymphoma 45, 2349-2351 (2004
85. Cross T. J. S., et al. Imatinib mesylate as a cause of acute liver failure. Am. J. Hematol. 81, 189-192 (2006
86. Pariente A., et al. Imatinib mesylate-induced acute hepatitis in a patient treated for gastrointestinal stromal tumour. Eur. J. Gastroenterol. Hepatol. 18, 785-787 (2006
87. Dhalluin-Venier V., et al. Imatinib mesylate induced acute hepatitis with autoimmune features. Eur. J. Gastroenterol. Hepatol. 18, 1235-1237 (2006
88. Srinivasan, S., Parsa, V., Liu, C. Y., & Fontana, J. A. Trastuzumab-induced hepatotoxicity. Ann. Pharmacother. 42, 1497-1501 (2008
89. Pessaux P., et al. Targeted molecular therapies (cetuximab and bevacizumab) do not induce additional hepatotoxicity: preliminary results of a case-control study. Eur. J. Surg. Oncol. 36, 575-582 (2010
90. Lin N. U., et al. Fatal hepatic necrosis following imatinib mesylate therapy. Blood 102, 3455-3456 (2003
91. Robert C., et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 6, 491-500 (2005
92. Joshi S. S., et al. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer 116, 3916-3923 (2010
93. Jatoi A., et al. Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in North Central Cancer Treatment Group Study N0147. Oncology 77, 120-123 (2009
94. Baas J. M., et al. Recommendations on management of EGFR inhibitor-induced skin toxicity: a systematic review. Cancer Treat. Rev. 38, 505-514 (2012
95. Bachet, J. B., et al. Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review. Oncologist 17, 555-568 (2012
96. Lipworth, A. D., Robert, C., & Zhu, A. X. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology 77, 257-271 (2009
97. Nagore, E., Insa, A., & Sanmartín, O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome: ncidence, recognition and management. Am. J. Clin. Dermatol. 1, 225-234 (2000
98. Segaert S., et al. Skin toxicities of targeted therapies. Eur. J. Cancer 45 (Suppl. 1), 295-308 (2009
99. Lévy E., et al. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer. J. Clin. Oncol. 16, 3537-3541 (1998
100. Escudier, B., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125-134 (2007); erratum 357, 203 (2007
101. Motzer R. J., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115-124 (2007
102. Breaker K., et al. Skin cancer associated with the use of sorafenib and sunitinib for renal cell carcinoma. Dermatol. Surg. 39, 981-987 (2013
103. Arnault J. P., et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J. Clin. Oncol. 27, e59-e61 (2009
104. Chapman P. B., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516 (2011
105. Hauschild, A., et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380, 358-365 (2012
106. Lacouture, M. E., Boerner, S. A., & Lorusso, P. M. Non-rash skin toxicities associated with novel targeted therapies. Clin. Lung Cancer 8, S36-S42 (2006
107. Kyllo, R. L., & Anadkat, M. J. Dermatologic adverse events to chemotherapeutic agents, part 1: cytotoxics, epidermal growth factor receptors, multikinase inhibitors, and proteasome inhibitors. Semin. Cutan. Med. Surg. 33, 28-39 (2014
108. Ennslin, C. J., Rosen, A. C., Wu, S., & Lacouture, M. Pruritus in patients treated with targeted cancer therapies: systematic review and meta-Analysis. J. Am. Acad. Dermatol. 69, 708-720 (2013
109. Vanneste, L., et al. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients. J. Eur. Acad. Dermatol. Venereol. 29, 61-68 (2015
110. Yano, K., Brown, L. F., & Detmar, M. Control of hair growth and follicle size by VEGF-mediated angiogenesis. J. Clin. Invest. 107, 409-417 (2001
111. Shah, D. R., Dholakia, S., & Shah, R. R. Effect of tyrosine kinase inhibitors on wound healing and tissue repair: implications for surgery in cancer patients. Drug Saf. 37, 135-149 (2014
112. Johannsen, M., et al. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. Eur. Urol. 55, 1430-1439 (2009
113. Johannsen M., et al. Outcome of treatment discontinuation in patients with metastatic renal cell carcinoma and no evidence of disease following targeted therapy with or without metastasectomy. Ann. Oncol. 22, 657-663 (2011
114. Harshman L. C., et al. Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC). Urol. Oncol. 31, 379-385 (2013
115. Qi, W. X., Sun, Y. J., Shen, Z., & Yao, Y. Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-Analysis of 24 phase III clinical trials. J. Chemother. 27, 40-51 (2015
116. Myung H. J., et al. Sorafenib-induced interstitial pneumonitis in a patient with hepatocellular carcinoma: a case report. Gut Liver 4, 543-546 (2010
117. Barber, N. A., & Ganti, A. K. Pulmonary toxicities from targeted therapies: a review. Target Oncol. 6, 235-243 (2011
118. Inoue A., et al. Severe acute interstitial pneumonia and gefitinib. Lancet 361, 137-139 (2003
119. Danson, S., Blackhall, F., Hulse, P., & Ranson, M. Interstitial lung disease in lung cancer: separating disease progression from treatment effects. Drug Saf. 28, 103-113 (2005
120. Suzuki M., et al. Recurrent gefitinib-induced interstitial lung disease. Intern. Med. 47, 533-536 (2008
121. Seidel C., et al. Recall pneumonitis during systemic treatment with sunitinib. Ann. Oncol. 21, 2119-2120 (2010
122. Grimminger, F., Günther, A., & Vancheri, C. The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis. Eur. Respir. J. 45, 1426-1433 (2015
123. Kantarjian H., et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 109, 5143-5150 (2007
124. Khoury H. J., et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood 119, 3403-3412 (2012
125. Stephens, J., Carpiuc, K. T., & Botteman, M. The burden of managing pleural effusions in patients with chronic myelogenous leukemia post-imatinib failure: a literature-based economic analysis. Int. J. Gen. Med. 3, 31-36 (2010
126. Shah N. P., et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and-intolerant chronic-phase chronic myeloid leukemia. J. Clin. Oncol. 26, 3204-3212 (2008
127. Kim D., et al. Long-Term pattern of pleural effusion from chronic myeloid leukemia patients in second-line dasatinib therapy. Int. J. Hematol. 94, 361-371 (2011
128. Peerzada, M. M., Spiro, T. P., & Daw, H. A. Pulmonary toxicities of biologics: a review. Anticancer Drugs 21, 131-139 (2010
129. Bouldouyre, M. A., Cohen, P., & Guillevin, L. Severe bronchospasm associated with rituximab for refractory Churg-Strauss syndrome. Ann. Rheum. Dis. 68, 606 (2009
130. Burton, C., Kaczmarski, R., & Jan-Mohamed, R. Interstitial pneumonitis related to rituximab therapy. N. Eng. J. Med. 348, 2690-2691 (2003
131. Leon, R. J., Gonsalvo, A., Salas, R., & Hidalgo, N. C. Rituximab-induced acute pulmonary fibrosis. Mayo Clin. Proc. 79, 953 (2004
132. Johnson D. H., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 22, 2184-2191 (2004
133. Sachdeva, A., & Matuschak, G. M. Diffuse alveolar hemorrhage following alemtuzumab. Chest 133, 1476-1478 (2008
134. Perazella, M. A. Onco-nephrology: renal toxicities of chemotherapeutic agents. Clin. J. Am. Soc. Nephrol. 7, 1713-1721 (2012
135. Gordon M. S., et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. 19, 843-850 (2001
136. Eremina V., et al. VEGF inhibition and renal thrombotic microangiopathy. N. Engl. J. Med. 358, 1129-1136 (2008
137. Zhu, X., Wu, S., Dahut, W. L., & Parikh, C. R. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-Analysis. Am. J. Kidney Dis. 49, 186-193 (2007
138. Bollée G., et al. Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol. Dial. Transplant. 24, 682-685 (2009
139. Abou-Alfa G. K., et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 24, 4293-4300 (2006
140. Chi K. N., et al. A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann. Oncol. 19, 746-751 (2008
141. Llovet J. M., et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390 (2008
142. Launay-Vacher, V., & Deray, G. Hypertension and proteinuria: a class-effect of antiangiogenic therapies. Anticancer Drugs 20, 81-82 (2009
143. Izzedine, H., et al. VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. Eur. J. Cancer 46, 439-448 (2010
144. Pou M., et al. Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia. Leuk. Lymphoma 44, 1239-1241 (2003
145. Foringer J. R., et al. Acute renal failure secondary to imatinib mesylate treatment in prostate cancer. Ann. Pharmacother. 39, 2136-2138 (2005
146. Dahut W. L., et al. A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin. Cancer Res. 14, 209-214 (2008
147. Schrag, D., Chung, K. Y., Flombaum, C., & Saltz, L. Cetuximab therapy and symptomatic hypomagnesemia. J. Natl Cancer Inst. 97, 1221-1224 (2005
148. Cao Y., et al. Meta-Analysis of incidence and risk of hypomagnesemia with cetuximab for advanced cancer. Chemotherapy 56, 459-465 (2010
149. Kelly, R. J., Billemont, B., & Rixe, O. Renal toxicity of targeted therapies. Target Oncol. 4, 121-133 (2009
150. Marinella, M. A., & Markert, R. J. Reversible posterior leucoencephalopathy syndrome associated with anticancer drugs. Intern. Med. J. 39, 826-834 (2009
151. Schiff, D., Wen, P. Y., & van den Bent, M. J. Neurological adverse effects caused by cytotoxic and targeted therapies. Nat. Rev. Clin. Oncol. 6, 596-603 (2009
152. Soffietti, R., Trevisan, E., & Rudá, R. Neurologic complications of chemotherapy and other newer and experimental approaches. Handb. Clin. Neurol. 121, 1199-1218 (2014
153. Bartynski, W. S. Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. AJNR Am. J. Neuroradiol 29, 1036-1042 (2008
154. van der Veldt A. A., et al. Reversible cognitive disorders after sunitinib for advanced renal cell cancer in patients with preexisting arteriosclerotic leukoencephalopathy. Ann. Oncol. 18, 1747-1750 (2007
155. Torino F., et al. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat. Rev. Clin. Oncol. 6, 219-228 (2009
156. Fallahi P., et al. Thyroid dysfunctions induced by tyrosine kinase inhibitors. Expert Opin. Drug Saf. 13, 723-733 (2014
157. Wolter P., et al. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br. J. Cancer 99, 448-454 (2008
158. Shinohara N., et al. The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma. Br. J. Cancer 104, 241-247 (2011
159. Funakoshi, T., & Shimada, Y. J. Risk of hypothyroidism in patients with cancer treated with sunitinib: a systematic review and meta-Analysis. Acta Oncol. 52, 691-702 (2013
160. Grossmann, M., Premaratne, E., Desai, J., & Davis, I. D. Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin. Endocrinol. (Oxf.) 69, 669-672 (2008
161. Tamaskar I., et al. Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann. Oncol. 19, 265-268 (2008
162. Sato S., et al. Clinical characteristics of thyroid abnormalities induced by sunitinib treatment in Japanese patients with renal cell carcinoma. Endocr. J. 57, 873-880 (2010
163. Konca Degertekin C., et al. Hyperthyroidism and thyroid autoimmunity induced by sorafenib in metastatic renal cell cancer. Endocrine 42, 756-757 (2012
164. de Groot J. W., et al. Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin. Pharmacol. Ther. 78, 433-438 (2005
165. Rini B. I., et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J. Natl Cancer Inst. 99, 81-83 (2007
166. Abdulrahman R. M., et al. Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination. J. Clin. Endocrinol. Metab. 95, 3758-3762 (2010
167. Kappers M. H., et al. Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression. J. Clin. Endocrinol. Metab. 96, 3087-3094 (2011
168. Huang, S. A. Physiology and pathophysiology of type 3 deiodinase in humans. Thyroid 15, 875-881 (2005
169. Makita, N., Miyakawa, M., Fujita, T., & Iiri, T. Sunitinib induces hypothyroidism with a markedly reduced vascularity. Thyroid 20, 323-326 (2010
170. Mannavola, D., et al. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J. Clin. Endocrinol. Metab. 92, 3531-3534 (2007
171. Braun D., et al. Tyrosine kinase inhibitors noncompetitively inhibit MCT8 mediated iodothyronine transport. J. Clin. Endocrinol. Metab. 97, E100-E105 (2012
172. Garfield, D., Hercbergs, A., & Davis, P. Unanswered questions regarding the management of sunitinib-induced hypothyroidism. Nat. Clin. Pract. Oncol. 4, 674 (2007
173. Huillard O., et al. Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic review. Eur. J. Cancer 50, 638-648 (2014
174. Renouf D. J., et al. Ocular toxicity of targeted therapies. J. Clin. Oncol. 30, 3277-3286 (2012
175. Davis, C. Drugs, cancer and end of life care: a case study of pharmaceuticalization? Soc. Sci. Med. 131, 207-214 (2015
176. Rosen A. C., et al. Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic. Am. J. Clin. Dermatol. 14, 327-333 (2013
177. Abernethy A. P., et al. Validation of the Patient Care Monitor (Version 2.0): a review of system assessment instrument for cancer patients. J. Pain Symptom Manage. 40, 545-558 (2010
178. Abernethy A. P., et al. Electronic patient-reported data capture as a foundation of rapid learning cancer care. Med. Care 48, S32-S38 (2010
179. Fojo, T., & Parkinson, D. R. Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much? Clin. Cancer Res. 16, 5972-5980 (2010
180. Fojo, T., & Grady, C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J. Natl Cancer Inst. 101, 1044-1048 (2009
181. Schnipper, L. E., Meropol, N. J., & Brock, D. W. Value and cancer care: toward an equitable future. Clin. Cancer Res. 16, 6004-6008 (2010
182. Meropol N. J., et al. American Society of Clinical Oncology guidance statement: the cost of cancer care. J. Clin. Oncol. 27, 3868-3874 (2009
183. Sobrero, A., & Bruzzi, P. Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval. J. Clin. Oncol. 27, 5868-5873 (2009
184. Overbeek J. A., et al. Costs of hospital events in patients with metastatic colorectal cancer. J. Med. Econ. 14, 656-661 (2011
185. Borovicka J. H., et al. Economic burden of dermatologic adverse events induced by molecularly targeted cancer agents. Arch. Dermatol. 147, 1403-1409 (2011
186. Bradbury P. A., et al. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer. J. Natl Cancer Inst. 102, 298-306 (2010
187. Wong A. S., et al. Targeted therapy at the end of life for patients with lung cancer. J. Palliat. Med. 13, 945-948 (2010
188. Saito A. M., et al. The effect on survival of continuing chemotherapy to near death. BMC Palliat. Care 10, 14 (2011
189. Earle C. C., et al. Aggressiveness of cancer care near the end of life: is it a quality-of care issue? J. Clin. Oncol. 26, 3860-3866 (2008
190. Soh T. I., et al. Targeted therapy at the end of life in advanced cancer patients. J. Palliat. Med. 15, 991-997 (2012
191. Hui D., et al. Targeted agent use in cancer patients at the end of life. J. Pain Symptom Manage. 46, 1-8 (2013
192. Mintzer, D. M., & Zagrabbe, K. On how increasing numbers of newer cancer therapies further delay referral to hospice: the increasing palliative care imperative. Am. J. Hosp. Palliat. Care 24, 126-130 (2007
193. Connor, S. R. U.S. hospice benefits. J. Pain Symptom Manage. 38, 105-109 (2009
194. Aldridge Carlson M. D., et al. Hospices' enrollment policies may contribute to underuse of hospice care in the United States. Health Aff. (Millwood) 31, 2690-2698 (2012
195. Cassaratt D. J., et al. The terrible choice: re evaluating hospice eligibility criteria for cancer. J. Clin. Oncol. 27, 953-959 (2008
196. Kumar, P., & Temel, J. S. End of life care discussions in patients with advanced cancer. J. Clin. Oncol. 31, 3315-3319 (2013
197. Wright A. A., et al. Place of death: correlations with quality of life of patients with cancer and predictors of bereaved caregivers' mental health. J. Clin. Oncol. 28, 4457-4464 (2010
198. Aldridge, M. D., Canavan, M., Cherlin, E., & Bradley, E. H. Has hospice use changed? 2000-2010 utilization patterns. Med. Care 53, 95-101 (2015
199. Teno, J. M., et al. Change in end of life care for Medicare beneficiaries: site of death, place of care, and health care transitions in 2000, 2005, and 2009. JAMA 309, 470-477 (2013
200. Obermeyer Z., et al. Association between the Medicare hospice benefit and health care utilization and costs for patients with poor-prognosis cancer. JAMA 312, 1888-1896 (2014
201. Rosell, R., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13, 239-246 (2012
202. Solomon B. J., et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N. Engl. J. Med. 371, 2167-2177 (2014
203. Food and Drug Administration. Gilotrif (afatinib): full prescribing information. Drugs@FDA [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/201292s000lbl.pdf (2013
204. Food and Drug Administration. Inlyta (axitinib): full prescribing information. Drugs@FDA [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/202324lbl.pdf (2012
205. Food and Drug Administration. Bosulif (bosutinib): full prescribing information. Drugs@FDA [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/203341lbl.pdf (2012
206. Food and Drug Administration. Cometriq (cabozantinib): full prescribing information. Drugs@FDA [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/203756lbl.pdf (2012
207. Food and Drug Administration. Zykadia (ceritinib): full prescribing information. Drugs@FDA [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/205755s000lbl.pdf (2014
208. Food and Drug Administration. Xalkori (crizotinib): full prescribing information. Drugs@FDA [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/202570s011lbl.pdf (2014
209. Food and Drug Administration. Tafinlar (dabrafenib): full prescribing information. Drugs@FDA [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/202806s000lbl.pdf (2013
210. Food and Drug Administration. Sprycel (dasatinib): full prescribing information. Drugs@FDA [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/021986s014lbl.pdf (2014
211. Food and Drug Administration. Tarceva (erlotinib): full prescribing information. Drugs@FDA [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/021743s019lbl.pdf (2014
212. Food and Drug Administration. Iressa (gefitinib): drug label. Drugs@FDA [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2005/021399s008lbl.pdf (2005
213. Food and Drug Administration. Imbruvica (ibrutinib): full prescribing information. Drugs@FDA [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/205552s001lbl.pdf (2014
214. Food and Drug Administration. Zydelic (idelalisib): full prescribing information. Drugs@FDA [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/205858lbl.pdf (2014
215. Food and Drug Administration. Gleevec (imatinib): full prescribing information. Drugs@FDA [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/021588s040lbl.pdf (2014
216. Food and Drug Administration. Tykerb (lapatinib): full prescribing information. Drugs@FDA [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/022059s016s017lbl.pdf (2013
217. Food and Drug Administration. Lenvima (lenvatinib): full prescribing information. Drugs@FDA [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2015/206947s000lbl.pdf (2015
218. Food and Drug Administration. Tasigna (nilotinib): full prescribing information. Drugs@FDA [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/022068s019lbl.pdf (2014
219. Food and Drug Administration. Ibrance (palbociclib): full prescribing information. Drugs@FDA [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2015/207103s000lbl.pdf (2015
220. Food and Drug Administration. Votrient (pazopanib): full prescribing information. Drugs@FDA [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/022465s019lbl.pdf (2014
221. Food and Drug Administration. Iclusig (ponatinib): full prescribing information. Drugs@FDA [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/203469s009lbl.pdf (2014
222. Food and Drug Administration. Stivarga (regorafenib): full prescribing information. Drugs@FDA [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/203085s001lbl.pdf (2013
223. Food and Drug Administration. Jakafi (ruxolitinib): full prescribing information. Drugs@FDA [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/202192s009lbl.pdf (2014
224. Food and Drug Administration. Nexavar (sorafenib): full prescribing information. Drugs@FDA [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/021923s016lbl.pdf (2013
225. Food and Drug Administration. Sutent (sunitinib): full prescribing information. Drugs@FDA [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/021938s027lbl.pdf (2014
226. Food and Drug Administration. Mekinist (trametinib): full prescribing information. Drugs@FDA [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/204114s001lbl.pdf (2014
227. Food and Drug Administration. Caprelsa (vandetanib): full prescribing information. Drugs@FDA [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/022405s007lbl.pdf (2014
228. Food and Drug Administration. Zelboraf (vemurafenib): full prescribing information. Drugs@FDA [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/202429s006lbl.pdf (2014
229. Food and Drug Administration. Kadcyla (ado-Trastuzumab emtansine): full prescribing information. Drugs@FDA [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/125427s033lbl.pdf (2014
230. Food and Drug Administration. Lemtrada (alemtuzumab): full prescribing information. Drugs@FDA [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/103948s5139lbl.pdf (2014
231. Food and Drug Administration. Avastin (bevacizumab): full prescribing information. Drugs@FDA [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/125085s305lbl.pdf (2014
232. Food and Drug Administration. Blincyto (blinatumomab): full prescribing information. Drugs@FDA [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/125557lbl.pdf (2014
233. Food and Drug Administration. Adcetris (brentuximab vedotin): full prescribing information. Drugs@FDA [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/125388-S056S078lbl.pdf (2014
234. Food and Drug Administration. Erbitux (cetuximab): full prescribing information. Drugs@FDA [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/125084s242lbl.pdf (2013
235. Food and Drug Administration. Xgeva (denosumab): full prescribing information. Drugs@FDA [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/125320s160lbl.pdf (2014
236. Food and Drug Administration. Zevalin (ibritumomab tiuxetan): full prescribing information. Drugs@FDA [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/125019s210s213lbl.pdf (2013
237. Food and Drug Administration. Yervoy (ipilimumab): full prescribing information. Drugs@FDA [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/125377s055lbl.pdf (2013
238. Food and Drug Administration. Opdivo (nivolumab): full prescribing information. Drugs@FDA [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/125554lbl.pdf (2014
239. Food and Drug Administration. Gazyva (obinutuzumab): full prescribing information. Drugs@FDA [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/125486-s008lbl.pdf (2014
240. Food and Drug Administration. Arzerra (ofatumumab): full prescribing information. Drugs@FDA [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/125326s060lbl.pdf (2014
241. Food and Drug Administration. Vectibix (panitumumab): full prescribing information. Drugs@FDA [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/125147s194lbl.pdf (2014
242. Food and Drug Administration. Perjeta (pertuzumab): full prescribing information. Drugs@FDA [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/125409s051lbl.pdf (2013
243. Food and Drug Administration. Cyramza (ramucirumab): full prescribing information. Drugs@FDA [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/125477s007lbl.pdf (2014
244. Food and Drug Administration. Rituxan (rituximab): full prescribing information. Drugs@FDA [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/103705s5432lbl.pdf (2014
245. Food and Drug Administration. Sylvant (siltuximab): full prescribing information. Drugs@FDA [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/125496s000lbl.pdf (2014
246. Food and Drug Administration. Bexxar (tositumomab): full prescribing information. Drugs@FDA [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/125011s0126lbl.pdf (2012
247. Food and Drug Administration. Herceptin (trastuzumab): full prescribing information. Drugs@FDA [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/103792s5311lbl.pdf (2014
248. Nagore, E., Insa, A., & Sanmartin, O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome: incidence, recognition and management. Am. J. Clin. Dermatol. 1, 225-234 (2000